Adherence to therapy in multiple sclerosis and schizophrenia;Therapieadhärenz bei Multipler Sklerose und Schizophrenie

Fortschritte der Neurologie Psychiatrie

Volumn 78, Issue 3, 2010, Pages 139-146

  Bussfeld, Patrick ^a   Czekalla, J ^b,c  

^a BAYER PHARMA AG   (Germany)

^b Bayer Schering Pharma ^*  (Germany)

^c UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Adherence; Compliance; Multiple sclerosis; Schizophrenia

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

DISEASE COURSE; EDUCATION PROGRAM; HEALTH SERVICE; HUMAN; MULTIPLE SCLEROSIS; PATIENT COMPLIANCE; PSYCHOEDUCATION; REVIEW; SCHIZOPHRENIA; TREATMENT INDICATION;

ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; HUMANS; MULTIPLE SCLEROSIS; PATIENT COMPLIANCE; PATIENT EDUCATION AS TOPIC; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 77949300342     PISSN: 07204299     EISSN: 14393522     Source Type: Journal    
DOI: 10.1055/s-0029-1245148     Document Type: Review

References (55)

1. Sabaté E. Adherence to Long-term Therapies: Evidence for Action. WHO 2003 Genf
2. Hayes E et al. Alliance not compliance: coaching strategies to improve type 2 diabetes outcomes. JAm Acad Nurse Pract 2008 20 (3) 155-162
3. Ownby R L. Medication adherence and cognition. Medical, personal and economic factors influence level of adherence in older adults. Geriatrics 2006 61 (2) 30-35
4. Owen R R. et al. Medication noncompliance and substance abuse among patients with schizophrenia. Psychiatr Serv 1996 47 (8) 853-858
5. DiMatteo M R. Patient adherence to pharmacotherapy: the importance of effective communication. Formulary 1995 30 (10) 596-598, 601-602, 605
6. Lacro J P. et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. JClin Psychiatry 2002 63 (10) 892-909
7. Claxton A J., Cramer J J., Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001 23 (8) 1296-1310
8. Bruce J M., Hancock L M., Lynch S G. Objective adherence monitoring in multiple sclerosis: initial validation and association with self-report. Mult Scler 2009 16 (1) 112-120
9. Brochet B, Lemaire G, Beddiaf A. [Reduction of injection site reactions in multiple sclerosis (MS) patients newly started on interferon beta 1b therapy with two different devices]. Rev Neurol (Paris) 2006 162 (6 7) 735-740
10. Kudielka B M., Broderick J E., Kirschbaum C. Compliance with saliva sampling protocols: electronic monitoring reveals invalid cortisol daytime profiles in noncompliant subjects. Psychosom Med 2003 65 (2) 313-319
11. Malhotra S et al. Drug related medical emergencies in the elderly: role of adverse drug reactions and non-compliance. Postgrad Med J 2001 77 (913) 703-707
12. Meichenbaum D TD. Therapiemotivation des Patienten. Bern Huber 1994
13. Greiner C. Aufbau eines TDM-Labors zur Individualisierung der Psychopharmakatherapie von Patienten mit affektiven Störungen. Göttingen Saska Verlag 2008 212 ff.
14. Hiemke C. Therapeutic drug monitoring in neuropsychopharmacology: does it hold its promises? Eur Arch Psychiatry Clin Neurosci 2008 258 (Suppl 1) 21-27
15. Baumann P et al. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 2004 37 (6) 243-265
16. Hayes T L. et al. An electronic pillbox for continuous monitoring of medication adherence. Conf Proc IEEE Eng Med Biol Soc 2006 1 6400-6403
17. Kelly G R., Scott J E., Mamon J. Medication compliance and health education among outpatients with chronic mental disorders. Med Care 1990 28 (12) 1181-1197
18. Zygmunt A et al. Interventions to improve medication adherence in schizophrenia. Am J Psychiatry 2002 159 (10) 1653-1664
19. Weiden P J., Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995 21 (3) 419-429
20. Lieberman J A. et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005 353 (12) 1209-1223
21. Schorr S G., Brouwers J R., Taxis K. [If drugs are not taken how different antipsychotics influence compliance of schizophrenic patients]. Fortschr Neurol Psychiatr 2007 75 (8) 473-477
22. Kemp R et al. Compliance therapy in psychotic patients: randomised controlled trial. Bmj 1996 312 (7027) 345-349
23. Olfson M et al. Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiatr Serv 2000 51 (2) 216-222
24. Oehl M, Hummer M, Fleischhacker W W. Compliance with antipsychotic treatment. Acta Psychiatr Scand 2000 Suppl 407 83-86
25. Maccann T, Boardmann G, Clark E. Risk profiles for non-adherence to antipsychotic medications. Journal of Psychiatric and Mental Health Nursing 2008 15 622-629
26. Massand P NM. Improving adherence to antipsychotic pharmacotherapy. Current Clinical Pharmacology 2006 1 (1) 47-56
27. Eijken M van et al. Interventions to improve medication compliance in older patients living in the community: a systematic review of the literature. Drugs Aging 2003 20 (3) 229-240
28. M. S. T. K.G. Aktuelle Therapieempfehlungen. 2006
29. Leitlinien der DGN 2008 Stuttgart Thieme 2008 4. ed
30. Kurtzke J F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983 33 (11) 1444-1452
31. Rio J et al. Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult Scler 2005 11 (3) 306-309
32. ORourke K E., Hutchinson M. Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns. Mult Scler 2005 11 (1) 46-50
33. Kern S, Reichmann H, Ziemssen T. Therapieadhärenz in der neurologischen Praxis. Nervenarzt 2008 79 877-890
34. Tremlett H L., Oger J. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. Neurology 2003 61 (4) 551-554
35. Milanese C et al. A post-marketing study on interferon beta 1b and 1a treatment in relapsing-remitting multiple sclerosis: different response in drop-outs and treated patients. JNeurol Neurosurg Psychiatry 2003 74 (12) 1689-1692
36. Smith C M., Barzman D, Pristach C A. Effect of patient and family insight on compliance of schizophrenic patients. JClin Pharmacol 1997 37 (2) 147-154
37. Dolder C R. et al. Interventions to improve antipsychotic medication adherence: review of recent literature. JClin Psychopharmacol 2003 23 (4) 389-399
38. Falloon I R. et al. Family management in the prevention of morbidity of schizophrenia. Clinical outcome of a two-year longitudinal study. Arch Gen Psychiatry 1985 42 (9) 887-896
39. Walburn J et al. Systematic review of patient and nurse attitudes to depot antipsychotic medication. Br J Psychiatry 2001 179 300-307
40. Heres S et al. Attitudes of psychiatrists toward antipsychotic depot medication. JClin Psychiatry 2006 67 (12) 1948-1953
41. West J C. et al. Use of depot antipsychotic medications for medication nonadherence in schizophrenia. Schizophr Bull 2008 34 (5) 995-1001
42. Tattan T M., Creed F H. Negative symptoms of schizophrenia and compliance with medication. Schizophr Bull 2001 27 (1) 149-155
43. Heres S et al. The attitude of patients towards antipsychotic depot treatment. Int Clin Psychopharmacol 2007 22 (5) 275-282
44. Patel M X. et al. A cross-sectional study of patients' perspectives on adherence to antispychotic medication: depot versus oral. JClin Psychiatry 2008 69; 10 1548-1556
45. Morken G, Widen J H., Grawe R W. Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia. BMC Psychiatry 2008 8 32
46. Abhijnhan A et al. Depot fluspirilene for schizophrenia. Cochrane Database Syst Rev 2007 1 CD001718
47. Quraishi S, David A. Depot flupenthixol decanoate for schizophrenia or other similar psychotic disorders. Cochrane Database Syst Rev 2000 2 CD001470
48. Cramer J A. et al. Patient satisfaction with an injection device for multiple sclerosis treatment. Acta Neurol Scand 2006 113 (3) 156-162
49. Costello K, Conway K. Nursing management of MS patients receiving interferon beta-1b therapy. Rehabil Nurs 1997 22 (2) 62-66, 81
50. Forbes A et al. Impact of clinical nurse specialists in multiple sclerosis - synthesis of the evidence. JAdv Nurs 2003 42 (5) 442-462
51. Zettl U K., Goertsches R H. [Therapy monitoring in patients with multiple sclerosis based on transcriptomic analysis]. Fortschr Neurol Psychiatr 2009 77 (Suppl 1) S64-68
52. Kappos L P., Pohlmann U, Meier C. Betaferon in early relapsing remitting Multiple Sclerosis surveillance trial (BEST): Interim 2- and 4-year data. Poster presented at the 23 rd congress of the European Comitee for treatment and research in Multiple Sclerosis, Prague 11 14. October 2007 P179
53. Durelli L, Barbero P, Clerico M. A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis. Neurology 2006 67 (12) 2264, author reply 2264-2265
54. Pfeiffer P N., Ganoczy D, Valenstein M. Dosing frequency and adherence to antipsychotic medications. Psychiatr Serv 2008 59 (10) 1207-1210
55. Ruggieri R M. et al. Long-term interferon-beta treatment for multiple sclerosis. Neurol Sci 2003 24 (5) 361-364